VIM0423 / Vima Therapeutics - LARVOL DELTA

Vima tacks on $40M to series A, expands plans for lead programme into Parkinson's (Firstwordpharma Press Release) - "Vima plans to start a Phase II study of VIM0423 in Parkinson's disease mid-year..."

Financing • New P2 trial • Parkinson's Disease